# Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results
Ticker: APLS
Company: Apellis Pharmaceuticals
Source: Apellis Pharmaceuticals
Published: 2026-02-24 12:05 EST
Original Source URL: https://investors.apellis.com
## Summary

Full-year 2025 net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI ® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of

## Article Body
Full-year 2025 net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI ® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of
## Recent Company News
- 2026-03-31 10:59 EST — [Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology](https://biopharmsignal.com/news/APLS/biogen-to-acquire-apellis-enhancing-the-company-s-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology) — Source: Apellis Pharmaceuticals
- 2026-03-02 12:00 EST — [Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors](https://biopharmsignal.com/news/APLS/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors) — Source: Apellis Pharmaceuticals
- 2026-02-24 12:05 EST — [Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Apellis Pharmaceuticals
- 2026-02-23 12:00 EST — [Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference](https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference) — Source: Apellis Pharmaceuticals
- 2026-02-19 12:00 EST — [Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting](https://biopharmsignal.com/news/APLS/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting) — Source: Apellis Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)